Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer

Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer

Background Immunotherapy represented by programmed death protein-1 (PD-1) inhibitors has gradually become the standard treatment of advanced non-small cell lung cancer (NSCLC) in recent years, changing the treatment landscape of advanced NSCLC. However, most PD-1-related studies excluded patients wi...

Full description

Bibliographic Details
Main Author:	SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi
Format:	Article
Language:	zho
Published:	Chinese General Practice Publishing House Co., Ltd 2023-01-01
Series:	Zhongguo quanke yixue
Subjects:	aged\|carcinoma, non-small-cell lung\|immune checkpoint inhibitors\|programmed cell death 1 receptor blockades\|drug therapy\|treatment outcome\|safety
Online Access:	https://www.chinagp.net/fileup/1007-9572/PDF/zx20220567.pdf

Similar Items

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
by: Yasuhiro Chikaishi, et al.
Published: (2021-03-01)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
by: Jianqiong Yin, et al.
Published: (2022-04-01)

Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial
by: Tomoaki Sonoda, et al.
Published: (2023-06-01)

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
by: Hao YY, et al.
Published: (2021-12-01)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021-10-01)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
by: Xiuju Liang, et al.
Published: (2019-12-01)

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data
by: Yi-Quan Jiang, et al.
Published: (2021-01-01)

A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer
by: Yichao Han, et al.
Published: (2023-07-01)

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer
by: Daisuke Morinaga, et al.
Published: (2023-05-01)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
by: Zijing Liu, et al.
Published: (2023-01-01)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
by: Christian Sordo-Bahamonde, et al.
Published: (2023-08-01)

Enhancing the efficacy of immunotherapy using radiotherapy
by: Synat Keam, et al.
Published: (2020-01-01)

Tumor lysis with LTX-401 creates anticancer immunity
by: Wei Xie, et al.
Published: (2019-07-01)

Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer
by: Shuang ZHANG, et al.
Published: (2017-09-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
by: Mohd Nazzary Mamat @ Yusof, et al.
Published: (2023-08-01)

Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
by: Shumin Yuan, et al.
Published: (2020-11-01)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
by: Xin Bai, et al.
Published: (2021-12-01)

All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
by: Sukyung Song, et al.
Published: (2023-10-01)

Comparative efficacy and safety of first‐line treatments for advanced non‐small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta‐analysis
by: Rui Chen, et al.
Published: (2019-04-01)

Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer
by: Yin Yang, et al.
Published: (2023-11-01)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
by: Cheng S, et al.
Published: (2023-04-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
by: Jeongrae Kim, et al.
Published: (2022-02-01)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
by: Jessica M. Konen, et al.
Published: (2019-04-01)

Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis
by: Jincheng Du, et al.
Published: (2023-04-01)

Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)
by: Yu Wang, et al.
Published: (2024-01-01)

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
by: Julie Malet, et al.
Published: (2023-04-01)

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
by: Kellie N. Smith, et al.
Published: (2019-02-01)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
by: Jee Hee Yoon, et al.
Published: (2021-04-01)

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-02-01)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
by: Dylan J. Martini, et al.
Published: (2017-08-01)

Research progress on photodynamic therapy combined with PD-1/PD-L1 inhibitors in anti-tumor therapy
by: Yu Xin, Ye Tinglu
Published: (2023-02-01)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
by: Marion Thibaudin, et al.
Published: (2023-12-01)

Evading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound
by: Jeongjin Lee, et al.
Published: (2022-11-01)

Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
by: Wuyin Wang, et al.
Published: (2022-07-01)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
by: Wei Xie, et al.
Published: (2019-11-01)

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
by: María Rosario García Campelo, et al.
Published: (2021-10-01)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
by: Shingo Kitagawa, et al.
Published: (2020-07-01)

Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors
by: Xing Li, et al.
Published: (2020-10-01)

Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
by: Liming Wang, et al.
Published: (2022-02-01)